Ethyl {trans-4-[4-(hydroxymethyl)phenyl]cyclohexyl}acetate | 1031336-84-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl {trans-4-[4-(hydroxymethyl)phenyl]cyclohexyl}acetate
• 英文别名: trans-ethyl 2-4-((4-(hydroxymethyl)phenyl)cyclohexyl)acetate
• CAS: 1031336-84-1
• 化学式: C₁₇H₂₄O₃
• 分子量: 276.376
• InChiKey: BFXUNDLRLBYENP-CTYIDZIISA-N

物化性质

• 沸点：
  410.9±20.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.41
• 重原子数：
  20.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  46.53
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  Ethyl {trans-4-[4-(hydroxymethyl)phenyl]cyclohexyl}acetate 在 氢溴酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 1.5h， 以88%的产率得到Ethyl {trans-4-[4-(bromomethyl)phenyl]cyclohexyl}acetate
  参考文献：
  名称：

  Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1

  摘要：

  A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound 14. Oral administration at doses >= 0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.

  DOI：

  10.1021/jm201524g
• 作为产物：
  描述：

  Ethyl (trans-4-phenylcyclohexyl)acetate 在 aluminum (III) chloride 、 5%-palladium/activated carbon 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 为溶剂， -5.0~20.0 ℃ 、275.8 kPa 条件下， 反应 19.25h， 生成 Ethyl {trans-4-[4-(hydroxymethyl)phenyl]cyclohexyl}acetate
  参考文献：
  名称：

  Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1

  摘要：

  A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound 14. Oral administration at doses >= 0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.

  DOI：

  10.1021/jm201524g

文献信息

• [EN] INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME<br/>[FR] INHIBITEURS DE L'ENZYME DIACYLGLYCÉROL O-ACYLTRANSFÉRASE DE TYPE 1
  申请人：ABBOTT LAB

  公开号：WO2008067257A8

  公开（公告）日：2009-06-25